Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/3/2020
SIETES contiene 92954 citas

 
 
 1 a 20 de 55 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Gilead’s hepatitis C treatments reach $12.4B in profits during 2014. DIA Daily 2015:4 de febrero. [Ref.ID 98768]
2. Cita con resumen
Liang TJ, Ghany MG. Therapy of hepatitis C. Back to the future. N Engl J Med 2014;370:2043-7. [Ref.ID 97487]
3.Tiene citas relacionadas Cita con resumen
Hoofnagle JH, Sherker AH. Therapy for hepatitis C - the costs of success. N Engl J Med 2014;370:1552-3. [Ref.ID 97486]
4.Tiene citas relacionadas Cita con resumen
Afdhal N, Reddy R, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian M, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, for the ION-2 investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93. [Ref.ID 97483]
6.Tiene citas relacionadas
Hellard ME, Doyle JS. Interferon-free hepatitis C treatment: one pill to fit all?. Lancet 2014;383:491-2. [Ref.ID 97107]
7.
Anónimo. Emtricitabine. Un antirétroviral très proche de la lamivudine. Prescrire 2004;24:656. [Ref.ID 71642]
8.Enlace a cita original Cita con resumen
Zuger A. New guidelines for treating HIV infection contain few major changes. Journal Watch 2004;24:136. [Ref.ID 71365]
9.Tiene citas relacionadas Cita con resumen
Hughes MD, Soh CH, Brady MT, Dankner WM, Oleske JM. Long-term effects of protease-inhibitor-based combination therapy. Authors' reply. Lancet 2004;363:900-1. [Ref.ID 69449]
10.Tiene citas relacionadas Cita con resumen
Barbaro G. Long-term effects of protease-inhibitor-based combination therapy. Lancet 2004;363:900. [Ref.ID 69448]
11. Cita con resumen
Soh CH, Oleske JM, Brady MT, Spector SA, Borkowsky W, Burchett SK, Foca MD, Handelsman E, Jiménez E, Dankner WM, Hughes MD, for the Pediatric AIDS Clinical Trials Group. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003;362:2045-51. [Ref.ID 68527]
12.
Demeter LM, Hughes MD, Coombs RW, Jackson B, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med 2001;135:954-64. [Ref.ID 59905]
13.Tiene citas relacionadas
Sullivan JL, Luzuriaga K. The changing face of pediatric HIV-1 infection. N Engl J Med 2001;345:1568-9. [Ref.ID 59561]
14.Tiene citas relacionadas Cita con resumen
Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage III GR, Song LY, Dankner WM, Oleske JM, for the Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-8. [Ref.ID 59557]
15.
Visnegarwala F, Musher DM, White AC. HIV-1 protease inhibitors may interfere with the ubiquitous intracellular proteases. Ann Intern Med 2001;135:840. [Ref.ID 59311]
16.
John L, Marra F, Ensom MHH. Role of therapeutic drug monitoring for protease inhibitors. Ann Pharmacother 2001;35:745-54. [Ref.ID 57311]
17. Cita con resumen
Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30. [Ref.ID 53607]
18. Cita con resumen
Anónimo. Hypersensibilité à l'abacavir: gare à la réadministration. Prescrire 2000;20:671. [Ref.ID 53034]
19.
Guerra Romero L, Parras Vázquez F. Las resistencias a los antirretrovirales: un debate clínico, de salud pública y de política sanitaria. Med Clin (Barc) 2000;115:428-30. [Ref.ID 53029]
20.
Gutiérrez F, Moltó J, Escolano C, Mora A, Pasquau F, Gregori J, Nogueira E. Resistencias genotípicas a los fármacos antirretrovirales en fracasos terapéuticos con pautas de alta eficacia. Med Clin (Barc) 2000;115:401-4. [Ref.ID 53027]
Seleccionar todas
 
 1 a 20 de 55 siguiente >>